Dyadic International Past Earnings Performance
Past criteria checks 0/6
Dyadic International's earnings have been declining at an average annual rate of -5%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been growing at an average rate of 16.7% per year.
Key information
-5.0%
Earnings growth rate
-3.9%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | 16.7% |
Return on equity | -115.6% |
Net Margin | -234.4% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Is Dyadic International (NASDAQ:DYAI) In A Good Position To Deliver On Growth Plans?
Mar 14Is Dyadic International (NASDAQ:DYAI) In A Good Position To Invest In Growth?
Oct 28Here's Why We're Watching Dyadic International's (NASDAQ:DYAI) Cash Burn Situation
Jun 21We're Hopeful That Dyadic International (NASDAQ:DYAI) Will Use Its Cash Wisely
Oct 05Dyadic collaborates with Syngene International to develop a COVID-19 vaccine candidate
May 26We're Not Very Worried About Dyadic International's (NASDAQ:DYAI) Cash Burn Rate
May 03Dyadic International's (NASDAQ:DYAI) Wonderful 318% Share Price Increase Shows How Capitalism Can Build Wealth
Feb 22Dyadic International (NASDAQ:DYAI) Is In A Good Position To Deliver On Growth Plans
Jan 18Do Insiders Own Lots Of Shares In Dyadic International, Inc. (NASDAQ:DYAI)?
Dec 10Dyadic International reports Q3 results
Nov 12Revenue & Expenses BreakdownBeta
How Dyadic International makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 3 | -7 | 6 | 3 |
30 Sep 23 | 3 | -7 | 6 | 3 |
30 Jun 23 | 3 | -7 | 6 | 3 |
31 Mar 23 | 3 | -8 | 6 | 4 |
31 Dec 22 | 3 | -10 | 6 | 5 |
30 Sep 22 | 2 | -12 | 6 | 6 |
30 Jun 22 | 2 | -12 | 7 | 8 |
31 Mar 22 | 3 | -12 | 7 | 8 |
31 Dec 21 | 2 | -13 | 7 | 8 |
30 Sep 21 | 2 | -11 | 6 | 7 |
30 Jun 21 | 2 | -12 | 6 | 6 |
31 Mar 21 | 2 | -10 | 6 | 5 |
31 Dec 20 | 2 | -9 | 6 | 4 |
30 Sep 20 | 2 | -9 | 6 | 4 |
30 Jun 20 | 2 | -8 | 5 | 4 |
31 Mar 20 | 2 | -8 | 6 | 4 |
31 Dec 19 | 2 | -8 | 6 | 4 |
30 Sep 19 | 2 | -7 | 5 | 4 |
30 Jun 19 | 2 | -7 | 5 | 4 |
31 Mar 19 | 2 | -6 | 4 | 3 |
31 Dec 18 | 1 | -6 | 4 | 3 |
30 Sep 18 | 1 | -7 | 4 | 3 |
30 Jun 18 | 1 | -7 | 4 | 3 |
31 Mar 18 | 1 | -6 | 5 | 3 |
31 Dec 17 | 1 | -2 | 5 | 2 |
30 Sep 17 | 1 | -3 | 6 | 1 |
30 Jun 17 | 1 | -2 | 6 | 1 |
31 Mar 17 | 1 | -1 | 6 | 1 |
31 Dec 16 | 1 | -4 | 5 | 1 |
30 Sep 16 | 0 | -2 | 4 | 1 |
30 Jun 16 | 0 | 0 | 4 | 1 |
31 Mar 16 | 0 | -2 | 4 | 0 |
31 Dec 15 | 0 | -1 | 4 | 0 |
30 Sep 15 | 0 | -2 | 4 | 0 |
30 Jun 15 | -6 | -4 | 4 | -1 |
31 Mar 15 | -3 | -5 | 4 | 0 |
31 Dec 14 | 0 | -5 | 5 | 0 |
30 Sep 14 | 4 | -5 | 6 | 0 |
30 Jun 14 | 14 | -6 | 7 | 2 |
31 Mar 14 | 18 | -1 | 6 | 1 |
31 Dec 13 | 17 | 0 | 6 | 1 |
30 Sep 13 | 16 | -1 | 6 | 1 |
30 Jun 13 | 15 | 0 | 6 | 1 |
Quality Earnings: DYAI is currently unprofitable.
Growing Profit Margin: DYAI is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: DYAI is unprofitable, and losses have increased over the past 5 years at a rate of 5% per year.
Accelerating Growth: Unable to compare DYAI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: DYAI is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: DYAI has a negative Return on Equity (-115.6%), as it is currently unprofitable.